United States · FDA National Drug Code directory
ENTYVIO
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 64764-107_266293d6-dd28-4e38-81c2-4f518d95ef5d
- Product NDC
- 64764-107
- Form
- INJECTION, SOLUTION
- Composition / generic term
- vedolizumab
- Labeler
- Takeda Pharmaceuticals America, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20230927
- Source listing expiry
- 20271231
Source-listed ingredients
- VEDOLIZUMAB — 108 mg/.68mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 TRAY in 1 CARTON (64764-107-11) / 1 SYRINGE in 1 TRAY (64764-107-10) / .68 mL in 1 SYRINGE · 64764-107-11
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →